Nilotinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
96.49
Gini
0.765
CATDS
0.020
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Nilotinib. Strongest target: DDR2 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 99.7% | 0.3% |
| 2 | EPHB1 | 98.8% | 1.2% |
| 3 | EPHB2 | 98.7% | 1.3% |
| 4 | DDR1 | 98.5% | 1.5% |
| 5 | RAF1 | 98.3% | 1.7% |
| 6 | ABL1 | 98.0% | 2.0% |
| 7 | PDGFRA | 97.9% | 2.1% |
| 8 | EPHA2 | 97.6% | 2.4% |
| 9 | ABL2_ARG | 96.9% | 3.1% |
| 10 | LCK | 95.1% | 4.9% |
| 11 | EPHB4 | 94.6% | 5.4% |
| 12 | EPHA4 | 94.4% | 5.6% |
| 13 | EPHA5 | 93.8% | 6.2% |
| 14 | FMS | 91.4% | 8.6% |
| 15 | EPHB3 | 89.9% | 10.1% |
| 16 | ZAK_MLTK | 87.8% | 12.2% |
| 17 | PDGFRB | 86.7% | 13.3% |
| 18 | BRAF | 85.8% | 14.2% |
| 19 | P38B_MAPK11 | 83.9% | 16.1% |
| 20 | ARAF | 81.8% | 18.2% |
Selectivity landscape
Where Nilotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Nilotinib.
Annotations
Sign in to read and post annotations.
Loading…